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T his chapter provides an overview of and an ori~nta tion to the psychiatric t reatment of children and adolescents . Treatment modalit ies as t hey appl y to adults are covered in the other chapters in Part IJI of t!-tis textbook. This chapter foc uses on what is different or unique in the t reatment of children and adolescents. Popper and colleagues, in C hapter 20 ("Disorders Usuall y First D iagnosed in Infancy, C hildhood, or Adolescence"), add ress ch ildhood psychopathology and outli ne t he treatme nt methods used for each disorder. T hroughout t his chapte r, the terms child and children refer to child ren of all ages, including adolescents, unless otherwise stated.
Techniques used in t he treatment of child psychiatric conditions have deve loped fro m two di ffe rent sources : t he tradi tions of understa ndi ng and t reat ing child ren based on developmental uniqueness and treatments that we re originall y designed for adults and we re t hen applied to chil dre n and ad olescents. In creasingly, more rigorous eva lu at ion and diag nostic proce dures have all owed greater specificity in the applicat ion of treatm en ts to our younger patients. In addit ion, expanding research o n the efficacy of specific therapeutic approaches continues to enJarge our armamentarium of empirically tested interve ntions.
The goa ls of all treatments are to reduce symptoms, to im prove emotional and behaviora l functioni ng, to remedy skill deficits, and to remove obstacles to norma l development. In contrast to the treatment of adults} a child is usuaUy brought by someone else, and in each case there are at least two clients: t he parent and the child, whose needs and desires may co nflict. In comparison wit h adults, children are more dependent on others fo r meeting their basic needs, they have fewe r cho ices of residence or activit ies, and they are required to atte nd school.
Evaluation
Psychiatric t reatment shou ld be preceded by a comprehensive clinical evaluat io n. In an emergency Situation, t reatment may have to be initiated fo Uowing a brief expedient assessment of t he chi ld's medical and psychological status. A more thorough eva luation should be accompli shed as soon as possible. True emergencies are, fortunately, uncommon, and in most cases the evaluation wi ll be completed before t reatment is begun. Of course, the process of assessment does not end w ith th e initiation of treatment but conti nues throughout.
The Am erican Academy of Chil d and Adolescent Psychi atry (AACAP) has produced a number of practice parameters as gu id es to eva luation and treatment of specific d isorders. Completed practice parameters are list ed in Table 33 -1.
The purpose of the comprehensive psychi atric assessment of children is similar to the assessment of adults: to determ ine the presence of one or more psychiat ric disorders and to recommend a well -fo rmulated tre atme nt plan that addresses the d isorder. Special considerations for children make evaluation different from t hat for adult Schizophrenia. O lder adolescents with schizophrenia may require medication dosages in the adult range. Young adolescents fall in hetween, and doses must be empirically determined because few data exist. It may require several weeks for full therapeutic effect to be achieved. Although data are sparse, they are suggestive of the benefit and safety of atypical antipsychotics as first-line agents in this population. Because of its potentially lethal side effects, clozapine should be used only in cases refractory to treatment with typical or other atypical agents and should be started at very low dosages-12.S mg/day or 25 mg/dayand titrated slowly upward (to minimize side effect s) to an expected dosage range of 25-500 mg/day. Risperidone should also be initiat ed at low doses (0.5-1.0 mg) and titrated slowly, to prevent development of EPS, up to an 
Pervasive developmental disorders. It is important
to give a trial of sufficient length to determine if the dru g is effective! barring serious side effects requiring immediate discontinuation . Typical daily doses are 0.5-4.0 mg of haloperidol. If the drug appears to be helpful, it should be conti nu ed for at least several months. At 3-to 6-month intervals, the drug should be discontinued to observe for withdrawal dyskinesias and to determine if the drug continues to be necessary. Some children m ay have physical withdrawal symptoms or a rebound phenomenon consisting of worsening of behavior for up to 8 weeks after the medication is stopped (M. Campbell et al. 1985) . Developmentally disturbed children treated with risperidone may benefit from dosages as low as 0.5-1.0 mg/day (Fisman and Steele 1996; Masi et al. 2001) but may require doses up to 6.0 mg/day (Perry et al. 1997) . Therapeutic daily dosages for o la nza pine ma y range from 5.0 to 20.0 mg.
Tourette's disorder. Careful monitoring of patients with Tourette's disorder for several months before starting medication is possible, since this is a chroni c d isorder and not usually an emergency_ This monitoring permits the clinician to establish a baseline of symptom s and to assess the need for psychological and educational interventions. An initial dose of haloperidol is 0.5 mg/day. It may be slowly increased up to 1-3 mg/day, divided in twice-daily doses (Cohen et al. 1992) . Pimozide, which may be given in a single daily dose, is started at 1 mg/day and may be gradually increased to a m aximum of 6-10 mg/ day (0.2 mg/kg). The usual dose range is 2-6 mg/day (Cohen et al. 1992) . Risperidone doses in t he range of 1.0-2.5 mg/ day appear to be useful (Lombroso et al. 1995) . Sallee et al. (2000) initiated ziprasidone at 5 mg/ day, titrating as high as 40 mg/day to achieve clinical effect in children with Tourette's disorde r.
Risks and Side Effects
Acute EPS, including dystonic reactions, parkinsonian tremor, rigidity and drooli ng, and akathisia, occur as in adults. Laryngeal dystonia is potentially fatal. Acute dystonia may be treated with oral or intramuscular diphenhydramine, 25 m g or 50 mg, or benztropine mesylate, 0.5-2.0 mg. Adolescent boys seem to be more vulnerable to acute dystonic rea ctions than are adult patients, so the physician may be ll10re inclined to use prophylactic antiparkinsonian medication. In children, however, reduction of antipsychotic dose is preferable to t he use of antiparkinsonian agents (M. Campbell et al. 1985) .
For treatment or prevention of parkinsonian symptoms, adolescents may be given the anticholinergic drug benztropine mesylate, 1-2 mg/day, in divided doses . Chronic parkinsonian symptoms are often drastically underrecognized by clinicians (Richardson et al. 1991) . The neuromuscular consequences may ilnpair the performance of age-appropriate activities, and the subjective effects may lead to noncompliance with medication. Akathisia may be especially difficult to identify in young patients or those with limited verbal abilities.
Tardive or withdrawal dyskinesias, some transient but others irreversible, seen in 8%-5 1 % of antipsychotictreated chi ldren and adolescents (M. Campbell et al. 1985) , mandate cautio n regarding casual use of these , drugs. Tardive dyskinesia has been documented in children and adolescents after as brief a period of treatment as 5 months (Herskowitz 1987) and may appear even during periods of constant medication dose. Cases of tardive d yskin esia have been reported in you ths t reated with risperidone (Feeney and Klykylo 1996) , indicating that atypical anti psychotics may also cause this serious adverse reaction. In children with autism or Tourette's disord er, it may be especially difficult to distinguish medication-induced movements from those characteristic of the· disorder. Before patients begin taking an antipsychotic medication, they should be examined carefully for abnormal movements by using a scale such as the Abnormal Invo luntary Movement Scale (AIMS 1988) and should be periodically reexamined . Parents and patients (if they are able) should receive regular explanations of the risk of movement disorders. Potentially. fatal neuroleptic m aligna nt syndrome has been reported \"{iih antipsychotic agents in children and adolescents (Silva et al. 1999) , with a presentation similar to that seen in adults.
